Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Specific glycosylated peptides of clusterin are found associated with hippocampal atrophy. The glycosylation of clusterin from human plasma was comprehensively analyzed and characterized using mass spectrometry (MS)-based glycoproteomics analysis. All six known N-glycosylation sites are covered, three in the alpha subunit (α64N, α81N and α123N) and three in the beta subunit (β64N, β127N, and β147N). More detailed structural characterization of clusterin glycopeptides was also performed, demonstrating the presence of glycosylated peptides and their corresponding glycans. Using liquid chromatography-tandem mass spectrometry (LC-MS/MS), we have determined the differences in the glycoforms associated at each of the different glycosylation sites in plasma clusterin obtained from subjects of low hippocampal atrophy (n = 13) and high hippocampal atrophy (n = 14). In our pilot study, the β64N site shows the most significant regulations between clinical groups. Eight β64N glycoforms are significantly reduced in patients with high atrophy compared with those with low atrophy, which demonstrates the utility of clusterin isoforms as diagnostic and prognostic Alzheimer's disease (AD) markers. These results provide a novel and robust workflow suitable for rapid verification of specific clusterin glycoforms with utility as AD biomarkers.

Original publication

DOI

10.1021/acs.jproteome.5b00892

Type

Journal article

Journal

J Proteome Res

Publication Date

04/12/2015

Volume

14

Pages

5063 - 5076

Keywords

Alzheimer’s disease, and biomarker, clusterin, glycosylation, hippocampal atrophy, mass spectrometry, selected reaction monitoring, Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Atrophy, Biomarkers, Clusterin, Cognition Disorders, Female, Glycosylation, Hippocampus, Humans, Male, Middle Aged, Molecular Sequence Data, Pilot Projects, Tandem Mass Spectrometry